Pharmaxis Limited (ASX:PXS) has been notified by the United States food and drug administration that its cystic fibrosis product Bronchitol has been accepted for standard review.
The healthcare company anticipates that Bronchitol could be available for US patients with cystic fibrosis in the second quarter of 2013.
CEO Dr Alan Robertson says the company is pleased the FDA has accepted the Bronchitol application and looks forward to making Bronchitol available to approximately 30,000 cystic fibrosis sufferers in the US.
In the first half of the 2012 financial year Pharmaxis reported a net loss of $19.5 million.
